InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
InflaRx (Nasdaq: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, announced it will release its Q3 2024 financial results on November 8, 2024, before market open. The company will also participate in the Guggenheim Securities Inaugural Healthcare Innovation Conference from November 11-13, 2024, in Boston, featuring a fireside chat on November 11th at 11:00 am ET. InflaRx specializes in developing inhibitors of complement activation factor C5a and its receptor C5aR, with their lead candidate vilobelimab and oral small molecule inhibitor INF904.
InflaRx (Nasdaq: IFRX), una compagnia biofarmaceutica focalizzata sulle terapie anti-infiammatorie, ha annunciato che rilascerà i suoi risultati finanziari del Q3 2024 l'8 novembre 2024, prima dell'apertura del mercato. La società parteciperà anche alla Guggenheim Securities Inaugural Healthcare Innovation Conference che si terrà a Boston dall'11 al 13 novembre 2024, con una conversazione informale l'11 novembre alle 11:00 ET. InflaRx è specializzata nello sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore C5aR, con il loro candidato principale vilobelimab e l'inibitore della molecola piccola orale INF904.
InflaRx (Nasdaq: IFRX), una empresa biofarmacéutica centrada en terapias antiinflamatorias, anunció que publicará sus resultados financieros del Q3 2024 el 8 de noviembre de 2024, antes de la apertura del mercado. La compañía también participará en la Guggenheim Securities Inaugural Healthcare Innovation Conference del 11 al 13 de noviembre de 2024 en Boston, con un chat informal el 11 de noviembre a las 11:00 am ET. InflaRx se especializa en desarrollar inhibidores del factor de activación del complemento C5a y su receptor C5aR, con su candidato principal vilobelimab y el inhibidor de molécula pequeña oral INF904.
InflaRx (Nasdaq: IFRX)는 항염증 치료제를 중심으로 하는 생명공학 기업으로, 2024년 3분기 재무 결과를 2024년 11월 8일 시장 개장 전에 발표할 것이라고 발표했습니다. 또한 2024년 11월 11일부터 13일까지 보스턴에서 열리는 구겐하임 증권 최초의 의료 혁신 회의에 참여하며, 11일 11:00 am ET에 그릴 대화에 참석할 예정입니다. InflaRx는 보완 활성화 인자 C5a와 그 수용체 C5aR의 억제제 개발을 전문으로 하며, 주요 후보 물질로 vilobelimab과 경구용 소분자 억제제 INF904를 보유하고 있습니다.
InflaRx (Nasdaq: IFRX), une entreprise biopharmaceutique axée sur les thérapies anti-inflammatoires, a annoncé qu'elle publiera ses résultats financiers du Q3 2024 le 8 novembre 2024, avant l'ouverture du marché. L'entreprise participera également à la Guggenheim Securities Inaugural Healthcare Innovation Conference qui se tiendra à Boston du 11 au 13 novembre 2024, avec une discussion informelle le 11 novembre à 11h00 ET. InflaRx se spécialise dans le développement d'inhibiteurs du facteur d'activation du complément C5a et de son récepteur C5aR, avec son candidat principal vilobelimab et l'inhibiteur de petite molécule orale INF904.
InflaRx (Nasdaq: IFRX), ein biopharmazeutisches Unternehmen, das sich auf entzündungshemmende Therapien konzentriert, gab bekannt, dass es seine Finanzergebnisse für Q3 2024 am 8. November 2024 vor Markteröffnung veröffentlichen wird. Das Unternehmen wird auch an der Guggenheim Securities Inaugural Healthcare Innovation Conference vom 11. bis 13. November 2024 in Boston teilnehmen, wo am 11. November um 11:00 Uhr ET ein informelles Gespräch stattfindet. InflaRx ist auf die Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und seines Rezeptors C5aR spezialisiert, mit ihrem Hauptkandidaten vilobelimab und dem oralen kleinen Molekülinhibitor INF904.
- None.
- None.
JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned.
In addition, InflaRx will participate in the following investor event:
Guggenheim Securities Inaugural Healthcare Innovation Conference
November 11-13, 2024, Boston, MA
Fireside chat: November 11th, 11:00 am ET
A link to register for the fireside chat live stream and its replay is available here. The company will also participate in one-on-one meetings at the conference.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) report Q3 2024 earnings?
Is InflaRx (IFRX) participating in any upcoming investor conferences?
What are InflaRx's (IFRX) main product candidates?
